GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Imagion Biosystems Ltd (ASX:IBX) » Definitions » Earnings per Share (Diluted)

Imagion Biosystems (ASX:IBX) Earnings per Share (Diluted) : A$-0.05 (TTM As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Imagion Biosystems Earnings per Share (Diluted)?

Imagion Biosystems's Earnings per Share (Diluted) for the six months ended in Dec. 2024 was A$0.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was A$-0.05.

Imagion Biosystems's EPS (Basic) for the six months ended in Dec. 2024 was A$0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 was A$-0.05.

Imagion Biosystems's EPS without NRI for the six months ended in Dec. 2024 was A$0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024 was A$-0.05.

During the past 3 years, the average EPS without NRIGrowth Rate was 42.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 22.40% per year.

During the past 8 years, Imagion Biosystems's highest 3-Year average EPS without NRI Growth Rate was 45.20% per year. The lowest was -15.30% per year. And the median was 42.30% per year.


Imagion Biosystems Earnings per Share (Diluted) Historical Data

The historical data trend for Imagion Biosystems's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imagion Biosystems Earnings per Share (Diluted) Chart

Imagion Biosystems Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Earnings per Share (Diluted)
Get a 7-Day Free Trial -0.28 -0.24 -0.35 -0.43 -0.05

Imagion Biosystems Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.14 -0.27 -0.16 -0.05 -

Competitive Comparison of Imagion Biosystems's Earnings per Share (Diluted)

For the Diagnostics & Research subindustry, Imagion Biosystems's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imagion Biosystems's PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Imagion Biosystems's PE Ratio distribution charts can be found below:

* The bar in red indicates where Imagion Biosystems's PE Ratio falls into.


;
;

Imagion Biosystems Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Imagion Biosystems's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2024 is calculated as

Diluted Earnings Per Share (A: Dec. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-2.067-0)/44.948
=-0.05

Imagion Biosystems's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2024 is calculated as

Diluted Earnings Per Share (Q: Dec. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-0.54-0)/57.271
=-0.01

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Imagion Biosystems  (ASX:IBX) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Imagion Biosystems Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Imagion Biosystems's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Imagion Biosystems Business Description

Traded in Other Exchanges
Address
5601 Oberlin Drive, Suite 100, San Diego, CA, USA, 92121
Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer.

Imagion Biosystems Headlines

No Headlines